04/20/2015> See all News
Presentations & Publications
A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve to, Refractory to or Have Relapsed on 5-Azacitadine: A Preliminary Analysis.
When you click on the button below, you will leave our website and will enter a website maintained by a third party that is not related to TetraLogic Pharmaceuticals, Inc.
We are providing a link to the third party's website solely as a convenience to you, because we believe that website may provide useful content. We are not, by referring or linking to the third party website, incorporating its contents into our own website. We do not endorse or guarantee, and we disclaim any responsibility for: the content, products or services offered on that website, its performance or interaction with your computer, its security and privacy policies and practices, and any consequences that may result from visiting that website.
By clicking on the button below, you acknowledge and agree to everything we say above.
You can also click on the link below to return to the TetraLogics Pharmaceuticals, Inc. website.